Arrhythmias & electrophysiology

Left Atrial Appendage Closure in Patients Considered Unsuitable for Oral Anticoagulation: Randomized Outcomes Through 5 Years in ASAP-TOO

J Am Coll CardiolPublished multinational randomized trial

Primary result · Primary effectiveness endpoint: ischemic stroke or systemic embolism; primary safety endpoint: death, ischemic stroke, systemic embolism, or 7-day device/procedure-related events requiring major interventionResult — go to the resultHazard ratio 0.73 95% CI 0.35–1.52
  • prematurely terminated

Authors' conclusion

In this prematurely terminated and underpowered trial, LAAC implantation was successful, with acceptable safety. Long-term estimates with LAAC were numerically favorable for thromboembolism but imprecise, while early bleeding was increased with the mandated antiplatelet regimen. These findings should be interpreted as exploratory and integrated with contemporary evidence and shared decision making. (Assessment of the WATCHMAN Device in Patients Unsuitable for Oral Anticoagulation [ASAP-TOO]; NCT02928497).

Study context

Population
Patients with atrial fibrillation, CHA2DS2-VASc score ≥2, and oral anticoagulation (OAC) unsuitabilityrandomized, target enrollment was 888 patients
Participants
481 patients
Comparison
Left atrial appendage closure (LAAC) with a Watchman device vs control treatment
  • LAACn = 320
  • Control treatmentn = 161reference
Primary endpoint
Primary effectiveness endpoint: ischemic stroke or systemic embolism; primary safety endpoint: death, ischemic stroke, systemic embolism, or 7-day device/procedure-related events requiring major intervention
Follow-up
Up to 5 years
Methodological details2:1 assignment
  • 2:1 assignment

Primary result

As reported in the abstract

Primary effectiveness endpoint: ischemic stroke or systemic embolism; primary safety endpoint…

Hazard ratio

0.73

95% CI 0.35–1.52

P = 0.39

By group

LAACvs control treatment
HR 0.73 (95% CI 0.35–1.52); P = 0.39
Primary safety endpoint, implant-attempted patients
1.0%

Further findings

OutcomeLAACControl treatmentHR (95% CI)
Disabling/fatal stroke (exploratory)Nominally less frequent with LAAC · exploratory analysis2.2%5.7%0.32 (0.10–1.05)

Conduct of the trial

Withdrawal, LAAC
7.8%
Withdrawal, control treatment
24.2%
Follow-up, control patients
median 876 days and 440.1 total patient-years
Follow-up, LAAC patients
median 1,768 days and 1,154.6 total patient-years
  • Enrollment stopped early because of slow accrual, accentuated by the COVID-19 pandemic
  • Fewer than the 34 events required to trigger the first planned interim analysis

Baseline characteristics

Age
75 ± 8 years
CHA2DS2-VASc score
4.6 ± 1.7
Prior intracranial/subdural hemorrhage
34%

Implantation success

Implantation success
97.8%

Safety

OutcomeLAACControl treatmentHR (95% CI)P value
Major bleeding22.1%15.7%1.64 (0.96–2.81)P = 0.067
  • Major bleeding: concentrated during the first 3 months

Pericardial effusions requiring intervention

Pericardial effusions requiring intervention
3

Original publication

Left Atrial Appendage Closure in Patients Considered Unsuitable for Oral Anticoagulation: Randomized Outcomes Through 5 Years in ASAP-TOO. J Am Coll Cardiol. Published 31 October 2026. doi:10.1016/j.jacc.2026.10.007

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.